See our exclusive index of companies on the move:
Explore Stocks- Top Stocks
- Top Australian Gold Stocks
- Top ASX Copper Stocks
- Top ASX Nickel Stocks
- Top ASX Rare Earth Stocks
- Top Battery Metals Stocks on the ASX
- Top Australian Lithium Stocks
- Top Graphite Miners on the ASX
- 10 ASX Cannabis Stocks
- Top ASX Tech Stocks
- Top AI Stocks on the ASX
- On Site
- About Australian Cannabis Investing
- About Australian Resource Investing
- About Australian Tech Investing
- About Australia Investing
- Of Interest
- ASEAN-Australia-New Zealand Trade Agreement
- Association of Southeast Asian Nations (ASEAN)
- Australian FAQ on ASEAN
- Australia Government on Foreign Investments

Botanix Pharmaceuticals announced a critical scheduling update from the US Drug Enforcement Administration regarding synthetic CBD used by its business associate Purisys.
Botanix Pharmaceuticals (ASX:BOT) noticed a boost thanks to a regulation change for the synthetic cannabidiol (CBD) produced with its business partner, Purisys.
In a press release issued on Monday (November 25), the company said that on November 22 Purisys received confirmation that its CBD, which carries less than 0.001 percent of tetrahydrocannabinol (THC), was removed from the scheduling as a controlled substance by the US Drug Enforcement Administration (DEA) within the Controlled Substances Act.
“This change in the regulation of synthetic CBD in the US will make a major difference to the speed of developing Botanix products and greatly reduces the risks and costs of clinical development,” Vince Ippolito, executive chairman and president of Botanix, said in a press release.
The executive said this ruling from the American federal authority comes at just the right time for the company since it’s getting ready for studies in its dermatology programs.
Botanix and Purisys are tied together by way of a supply agreement signed in October.
The duo is celebrating the change from the DEA; prior to this resolution, the use of synthetic CBD for clinical studies needed licensing from the federal agency. According to Botanix, this led to “significant management and cost overheads to Botanix’s pharmaceutical development activities.”
Shares of Botanix jumped nearly 5 percent on Monday when it first informed investors of the crucial change. As of Wednesday’s (November 27) trading session, the company is up nearly 5 percent for a price per share of AU$0.11.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Top News
FEATURED STOCKS
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.